US FDA accepts and grants priority review status to AstraZeneca’s …
WEB4 days ago · AstraZeneca’s supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The Food and Drug Administration (FDA) grants Priority Review to ...
AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with ...
WEB13 hours ago · Positive high-level results from the BATURA phase IIIb trial showed AstraZeneca’s Airsupra (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication ...
Immunovia acquires all blood samples required to clinically …
WEB4 hours ago · Immunovia, the pancreatic cancer diagnostics company, announces that the company has acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer. Concluding the sample collection effort marks a key milestone toward successfully completing the clinical ...
Boehringer Ingelheim’s Cyltezo to treat multiple chronic …
WEBFriday, May 3, 2024, 11:00 Hrs [IST] Boehringer Ingelheim Group, one of the largest producers of biologic medicines in the world, announced that the US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company's interchangeable biosimilar to Humira (adalimumab), to ...
US FDA accepts and granted Priority Review status to …
WEBAug 16, 2024 · US FDA accepts and granted Priority Review status to AstraZeneca’s sBLA for Imfinzi to treat patients with limited-stage SCLC: Cambridge, UK Friday, August 16, 2024, 16:00 Hrs [IST]
TopNews - Pharmabiz.com
WEBSep 28, 2024 · Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, pharma projects, pharma export & import, pharma laws & documents, pharma policies, pharma events, pharma company profiles, pharma studies, pharma marketing.
AstraZeneca to acquire clinical-stage biopharma company, Fusion …
WEBMar 20, 2024 · AstraZeneca to acquire clinical-stage biopharma company, Fusion Pharma for $2 billion: Cambridge, UK Wednesday, March 20, 2024, 11:00 Hrs [IST] AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs).
AstraZeneca completes acquisition of clinical-stage biotech …
WEBJul 16, 2024 · Cambridge, UK. Tuesday, July 16, 2024, 10:00 Hrs [IST] AstraZeneca announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on ...
Orchid Pharma’s enmetazobactam receives US FDA approval
WEBFeb 23, 2024 · Orchid Pharma’s enmetazobactam receives US FDA approval: Our Bureau, Mumbai Friday, February 23, 2024, 17:55 Hrs [IST] Chennai-based Orchid Pharma has received approval from the United States Food and Drug Administration (FDA) for its novel invention, ‘Enmetazobactam’.
Halozyme announces US FDA approval of Roche's Tecentriq …
WEBSep 14, 2024 · Halozyme Therapeutics, Inc. (Halozyme) announced that Roche received US Food and Drug Administration (FDA) approval for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) with Halozyme's Enhanze drug delivery technology. Tecentriq Hybreza can be injected subcutaneously in approximately 7 ...